SOUTH SAN FRANCISCO, Calif., Sept. 8, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB) today announced that the Company received a letter from the Staff of The NASDAQ Stock Market indicating that the Company has failed to regain compliance with NASDAQ Marketplace Rule 4310(c)(3), which requires the Company to have a minimum of $2,500,000 in stockholders’ equity, or $35,000,000 market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years, for continued listing on The NASDAQ Capital Market. On September 8, 2009, NASDAQ notified the Company that it had determined to delist the Company’s common stock from The NASDAQ Capital Market. Trading of the Company’s shares will be suspended effective at the opening of business on Thursday, September 10, 2009.
